Navigation auf


Rechtswissenschaftliche Fakultät Lehrstuhl Vokinger


We are an interdisciplinary team with backgrounds in law, medicine, health sciences, economics, finance, and statistics.

Research Areas

We conduct research in the following three core areas:

Interdisciplinary research at the intersection of law and medicine: Our objective is to improve access of patients and society to medicine in Europe, the US and around the world. Our focus lies on medicines, medical devices and digital health. We combine legal and empirical analysis and, based on the results, develop policies.

Interdisciplinary research at the intersection of law and technology: Our objective is to analyze the potential and challenges of emerging technologies (such as artificial intelligence-based applications), how innovative technologies are applied in the real world setting and how development and access could be fostered while mitigating risks. We combine legal and empirical analysis and, based on the results, develop policies.

Public law: We conduct traditional legal analysis in constitutional law and administrative law, often related but not limited to questions in medicine or innovative technologies.

Selected Publications

Our studies are published in leading journals in law, medicine and science (e.g., The New England Journal of Medicine, The British Medical Journal, JAMA, Lancet, Nature Medicine, Annals of Internal Medicine, Lancet Oncology, Cell, Cambridge University Press) and have been covered by the media (e.g., The New York Times, The LA Times, Boston Globe/Stat News, Forbes, Scientific American, SRF, Neue Zürcher Zeitung, Tagesanzeiger).

We collaborate closely with academics from other universities, for example, Harvard Medical School, London School of Economics and Political Science, or Technical University Munich.

Our research is funded by the Swiss National Science Foundation (SNSF), the Swiss Cancer Research Foundation (Krebsforschung Schweiz) and Kaiser Permanente Institute for Health Policy.

We advise governments (e.g., Federal Office of Public Health, Federal Department of Foreign Affairs) and international organizations (e.g., UN) in our areas of expertise.

Weiterführende Informationen

Ausgewählte Publikationen

Determinants of cancer drug pricing and how to overcome the cancer premium

Mehr zu Determinants of cancer drug pricing and how to overcome the cancer premium

Sources of Innovation in Gene Therapies — Approaches to Achieving Affordable Prices. NEJM 2023.


Reforming the World Health Organization's Essential Medicines List. Essential but Unaffordable. JAMA 2022.

Publication JAMA

Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis. The Lancet Ocology 2022.


Regulating AI in medicine in the United States and Europe. Nature Machine Intelligence 2021.


Analysis of launch and postapproval cancer drug pricing, clinical benefit, and policy implications in the US and Europe. JAMA Oncology 2021.


Approval of artificial intelligence and machine learning-based medical devices in the USA and Europe (2015-20): a comparative analysis. Lancet Digital Health 2021.

Publication JAMA

Clinical benefit of cancer drugs and prices in the US and Europe. Lancet Ocology 2020.

Publication JAMA

Lifecycle regulation of artificial intelligence- and machine learning based software devices in medicine. JAMA 2019.

Beitrag Jusletter

Re-Identifikation von Gerichtsurteilen durch "Linkage" von Daten(banken). Eine empirische Analyse anhand von Bundesgerichtsbeschwerden gegen (Preissfestsetzungs-) Verfügungen von Arzneimitteln. Jusletter 2019.

Social media